Compare Cassava Sciences Inc (FLNA) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Huntington Bancshares Incorporated — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Huntington Bancshares Incorporated trades at $18.46 (market cap $36.74B). The key difference: Huntington Bancshares Incorporated is far larger — about 691.4× Cassava Sciences Inc's market cap, and Huntington Bancshares Incorporated pays a 3.42% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | HBAN | |
|---|---|---|
Market Cap | $53.14M | $36.74B |
Sector | Health | Financials |
52-Week High | $4.64 | $19.27 |
52-Week Low | $1.09 | $15.02 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 3.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Huntington Bancshares (HBAN) trades at $17.85, down 0.45% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q1 2026 EPS of $0.25, beating expectations, and revenue growth to $8.13B in 2025. Analysts maintain a consensus price target of $20.25, with 49% recommending Buy. Recent news highlights expansion in Texas and strong Q1 results, though integration risks from acquisitions remain a focus.
HBAN presents a moderate growth opportunity with a P/E of 13.94 and ROE of 8.6%, supported by earnings beats and strategic expansions. Key risks include competitive pressures in regional banking and execution challenges from M&A activity. The stock's upside to the consensus target suggests potential appreciation, but investors should weigh margin trends and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
